Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study

• Published in: ESMO open Vol. 6; no. 6; p. 100328
• Main Authors: Tabernero, J., Velez, L., Trevino, T.L., Grothey, A., Yaeger, R., Van Cutsem, E., Wasan, H., Desai, J., Ciardiello, F., Yoshino, T., Gollerkeri, A., Maharry, K., Christy-Bittel, J., Kopetz, S.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-12-2021; Elsevier
• Subjects: adverse events; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Carbamates; cetuximab; Cetuximab - adverse effects; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; Colorectal Neoplasms - pathology; CRC; encorafenib; Humans; metastatic colorectal cancer; Mutation; Proto-Oncogene Proteins B-raf - genetics; Review; Sulfonamides; cetuximab; metastatic colorectal cancer; adverse events; CRC; encorafenib
• ISSN: 2059-7029; 2059-7029
• DOI: 10.1016/j.esmoop.2021.100328

Colorectal cancer is the second leading cause of cancer deaths worldwide, with a 5-year relative survival of 14% in patients with metastatic colorectal cancer (mCRC). Patients with BRAF V600E mutations, which occur in ∼10%-15% of patients with mCRC, have a poorer prognosis compared with those with wild-type BRAF tumours. The combination of the BRAF inhibitor encorafenib with the epidermal growth factor receptor inhibitor cetuximab currently represents the only chemotherapy-free targeted therapy approved in the USA and Europe for previously treated patients with BRAF V600E-mutated mCRC. As a class, BRAF inhibitors are associated with dermatologic, gastrointestinal, and renal events, as well as pyrexia and secondary skin malignancies. Adverse event (AE) profiles of specific BRAF inhibitors vary, however, and are affected by the specific agents given in combination. In patients with mCRC, commonly reported AEs of cetuximab monotherapy include infusion reactions and dermatologic toxicities. Data from the phase III BEACON CRC study indicate that the combination of encorafenib with cetuximab has a distinct safety profile. Here we review the most frequently reported AEs that occurred with this combination in BEACON CRC and best practices for managing and mitigating AEs that require more than standard supportive care.
•Encorafenib + cetuximab has a distinct safety profile in patients with BRAF V600E-mutated metastatic colorectal cancer.•Effective management strategies can mitigate the impact of AEs, prolonging treatment duration and benefits.•We provide guidance on managing gastrointestinal, skin, and renal AEs.•Specific guidance is given for the management of arthralgia, myalgia, fatigue, asthenia, headache, and pyrexia.